Abstract: The present invention relates to a D 25 polysaccharide compound whose lipid has been partially removed and to its derivatives, wherein at least 85% by weight, preferably 90% of the compound, exists in aqueous solution in monomeric form. The 30 kD molecular weight polysaccharide compound extracted from the membrane proteoglycan of the bacterium Klebsiella pneumoniae is mentioned in particular. The amount of palmitic fatty acids which is bound to it in esterified form does not exceed 0.01% by weight of the compound and the amount of palmitic fatty acids which is associated with it in the free form does not exceed 0.1% by weight of the compound.

Abstract: The present invention relates to an aerosol composition containing a carrier agent capable of recognizing and binding to inflammatory and tumor foci mobilizing macrophages in their immediate environment, and an aerosol substrate, characterized in that the said carrier agent consists of a polysaccharide compound selected from the compound D 25, extracted from the membrane proteoglycans of the bacterium Klebsiella pneumoniae and having a molecular weight of 30.+-.0.10 Kd, and the compound oxidized D 25 in which the galactofuranoser residue (Gal.sub.f) of the linear polysaccharide chain of D 25 has been converted to arabinose, and their amide, ester or ether type derivatives, as well as their quaternary ammonium derivatives and salts, and also the derivatives obtained by grafting of phosphatides.

Abstract: The present invention relates to a polysaccharide derivative, which is a derivative of D.25 in which the galactofuranose (Gal.sub.f) residues of the linear polysaccharide chain have been converted at least partly to arabinose.It also relates to the process for its preparation, to its use as an immunostimulant, and to pharmaceutical compositions containing the derivative.

Abstract: The invention relates to a polysaccharide derivative which is an amide, an ester, an ether, a salt or a quaternary ammonium derivative of D.25 with an amine, an acid or an alcohol.

Abstract: The present invention relates to a membrane polysaccharide of bacterial origin having the following quantitative analytical composition:______________________________________ galactose content 66 .+-. 6% content of hexoses other than galactose <1% hexosamine (glucosamine) content 8.5 .+-. 2% amino acid content 5 .+-. 2% fatty acid content <1% nucleic acid content <0.005% protein content <0.03% and molecular weight: 90,000 .+-. 10,000.

Abstract: The present invention relates to a method of preparing bacterial membranous proteoglycans with an action which induces interferon from soluble membranous proteoglycans of a strain of gram-negative bacterium, wherein the soluble membranous proteoglycans of a strain of gram-negative bacterium are hydrolyzed by lysozyme and the proteoglycans with a molecular weight between 200,000 and 400,000 are separated from the hydrolysis product.The products obtained are useful as a medicament.

Abstract: The present invention relates to a vaccinal complex containing a specific antigen. This is a vaccinal complex characterized in that it is composed of bacterial ribosomal RNA or fragments of bacterial ribosomal RNA on which are coupled from 1 to 5% by weight of a specific antigen of bacterial serotype. This complex may be used as a vaccine.

Abstract: This invention relates to a process for the preparation of purified bacterial membranal proteoglycans. The process comprises at least one step in which crude proteoglycans are treated in aqueous medium with a base or a hypobromite, followed by elimination of the excess reactant and the insoluble residue, the purified proteoglycans being present in aqueous solution. The thus obtained purified proteoglycans may be used as immunity adjuvants in vaccines without causing side-effects such as pyrogenic reactions.

Abstract: This invention relates to a non-specific immunostimulating preparation for the treatment of immunodeficits, such as those encountered in leprosy and cancer, characterized in that it contains as sole active principle one or more bacterial ribosomal RNA's extracted from the following strains:Klebsiella pneumoniaeSerratia marcescens

Abstract: Vaccines which comprise in association the ribosomal fraction extracted from the bacterias against which a protection is wanted, and the peptidoglycanes extracted from the membranes of at least one of the bacteria previously used.

Abstract: The present invention relates to an improved process for the preparation of plasminogen activator.This is a process for separating a plasminogen activator according to U.S. Pat. No. 3,998,947 characterized in that it comprises at least the following stages:(i) selective adsorption of the said activator on a support with specific affinity comprising soluble fragments of fibrin covalently bonded to an insoluble matrix; and(ii) elution of the activator from the fibrin bearing the adsorbed activator.The plasminogen activator obtained is useful in the prevention and treatment of thrombosis.

Abstract: This invention relates to a process for the preparation of purified bacterial membranal proteoglycans. The process comprises at least one step in which crude proteoglycans are treated in aqueous medium with a base or a hypobromite, followed by elimination of the excess reactant and the insoluble residue, the purified proteoglycans being present in aqueous solution. The thus obtained purified proteoglycans may be used as immunity adjuvants in vaccines without causing side-effects such as pyrogenic reactions.

Abstract: The present invention relates to a pharmaceutical composition comprising a plasminogen activator and a polysaccharide sulphate. The invention also covers a process for preparing the pharmaceutical composition and a process for preparing the plasminogen activator.The pharmaceutical compositions are useful in the treatment of circulatory disorders such as venous thromboses.

Abstract: A process for obtaining a plasminogen activator involves treating an acetone extract powder of organs of animals, such as the lungs and kidneys of pigs, calves, bullocks, horses, lambs or sheep or the ovaries of porcine, bovine or ovine animals, by suspension in an aqueous saline solution, taking up the precipitate obtained in an aqueous saline solution of greater ionic strength and lower pH-value, decanting the solution and precipitating therefrom at acidic pH by adding a salt or an organic solvent, further taking up the precipitate obtained in water or a saline solution, followed by repeated precipitation by adding a salt at a somewhat higher pH-value, finally taking up the precipitate obtained in water and dialyzing the solution, and optionally purifying the solution obtained.The activator obtained may be used as a medicament.